Author

Jeanne Ohrnberger

Observed name: J. Ohrnberger

Observed institutions: Mayo Clinic, Everist Health (United States)

OpenAlex ID: A5063090593

Generation and external validation of a tumor‐derived 5‐gene prognostic signature for recurrence of lymph node‐negative, invasive colorectal carcinoma

2012 · Peter F. Lenehan, Lisa A. Boardman, et al. · Cancer · 41

Novel Prostate Cancer Biomarkers Derived from Autoantibody Signatures

2015 · Matthew Schipper, George Wang, et al. · Translational Oncology · 22

Assessing prognosis by quantifying FcγRIIa on fixed platelets

2024 · David J Schneider, Heidi S Taatjes-Sommer, et al. · Bioanalysis · 6

New developments in prostate cancer screening using a novel cancer-specific, non-PSA biomarker assay derived from autoantibody signatures

2017 · Jason M. Hafron, Heng Yu, et al. · Journal of Medicine and Therapeutics · 3

External validation of a tumor derived 5-gene prognostic signature (OncoDefender-CRC) for recurrence (R) of stages I/II colorectal cancer (CRC).

2011 · P. F. Lenehan, L. A. Boardman, et al. · Journal of Clinical Oncology · 3

Risk assessment for high-grade prostate cancer using a novel cancer-specific biomarker assay derived from autoantibody signatures

2017 · Xiaoju Wang, Jason M. Hafron, et al. · Biomedical Research and Clinical Practice · 2

External validation of a tumor-derived 5-gene prognostic signature for recurrence (R) of stages I/II colon and stage I rectal cancer following potentially curative resection.

2011 · P. F. Lenehan, L. A. Boardman, et al. · Journal of Clinical Oncology · 2

Screening for prostate cancer: a clinical update for primary care providers using a novel, serum-based prostate cancer risk assessment multiplexed autoantibody assay

2017 · Gregory Allen, Heng Yu, et al. · Biomedical Research and Reviews · 1

Mp28-06 a Novel Serum Based Multiplexed 21 Autoantibody Assay to Predict High-grade Prostate Cancer at Initial Biopsy

2017 · Stephen Freedland, Sharat Singh, et al. · The Journal of Urology

Improved risk assessment using a novel cancer-specific biomarker assay derived from autoantibody signatures for men with non-aggressive prostate cancer who are not receiving treatment

2017 · Xiaoju Wang, Jason M. Hafron, et al. · Biomedical Research and Reviews

Works count: 10

Citation count: 80

H-index: 3

I10-index: 2